Idecabtagene vicleucel (Abecma)

Mechanism of action

From the NCI Drug Dictionary: A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells.

Toxicity management

• [Link to REMS program]

Diseases for which it is used

• Multiple myeloma

History of changes in FDA indication

• 3/26/2021: Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (Approval based on KarMMa)

Patient Drug Information

• idecabtagene vicleucel (Abecma) Package Insert

Also known as

• Code name: bb2121
• Generic name: ide-cel
• Brand name: Abecma